Life Extension Magazine

Life Extension Magazine June 2007

Cover Story

Congress Seeks to Ban DHEA

By William Faloon

By William Faloon



1. Ravaglia G, Forti P, Maioli F, et al. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. J Clin Endocrinol Metab. 1996 Mar;81(3):1173-8.

2. Ravaglia G, Forti P, Maioli F, et al. Dehydroepiandrosterone-sulfate serum levels and common age-related diseases: results from a cross-sectional Italian study of a general elderly population. Exp Gerontol. 2002 May;37(5):701-12.

3. Celec P, Starka L. Dehydroepiandrosterone—is the fountain of youth drying out? Physiol Res. 2003;52(4):397-407.

4. Glei DA, Goldman N. Dehydroepiandrosterone sulfate (DHEAS) and risk for mortality among older Taiwanese. Ann Epidemiol. 2006 Jul;16(7):510-5.

5. Mazat L, Lafont S, Berr C, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci USA. 2001 Jul 3;98(14):8145-50.

6. Stahl F, Schnorr D, Pilz C, Dorner G. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol. 1992;99(2):68-70.

7. Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA. Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiol. 2003 Oct;58(5):403-10.

8. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann NY Acad Sci. 1995 Dec 29;774:271-80.

9. Feldman HA, Johannes CB, Araujo AB, et al. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001 Jan 1;153(1):79-89.

10. Khalil A, Fortin JP, LeHoux JG, Fulop T. Age-related decrease of dehydroepiandrosterone concentrations in low density lipoproteins and its role in the susceptibility of low density lipoproteins to lipid peroxidation. J Lipid Res. 2000 Oct;41(10):1552-61.

11. Thomas N, Morris HA, Scopacasa F, Wishart JM, Need AG. Relationships between age, dehydro-epiandrosterone sulphate and plasma glucose in healthy men. Age Ageing. 1999 Mar;28(2):217-20.

12. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005 Sep;63(3):239-50.

13. Haden ST, Glowacki J, Hurwitz S, Rosen C, LeBoff MS. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int. 2000 Jun;66(6):414-8.

14. Paolisso G, Ammendola S, Rotondi M, et al. Insulin resistance and advancing age: what role for dehydroepiandrosterone sulfate? Metabolism. 1997 Nov;46(11):1281-6.

15. Kameda W, Daimon M, Oizumi T, et al. Association of decrease in serum dehydroepiandrosterone sulfate levels with the progression to type 2 diabetes in men of a Japanese population: the Funagata Study. Metabolism. 2005 May;54(5):669-76.

16. Beishuizen A, Thijs LG, Vermes I. Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve? Crit Care. 2002 Oct;6(5):434-8.

17. Aydin T, Karacan I, Demir SE, Sahin Z. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels. Clin Endocrinol (Oxf). 2005 Oct;63(4):467-9.

18. Osmanagaoglu MA, Okumus B, Osmanagaoglu T, Bozkaya H. The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women. J Womens Health (Larchmt). 2004 Nov;13(9):993-9.

19. Szathmari M, Szucs J, Feher T, Hollo I. Dehydroepiandrosterone sulphate and bone mineral density. Osteoporos Int. 1994 Mar;4(2):84-8.

20. Heinz A, Weingartner H, George D, et al. Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. Psychiatry Res. 1999 Dec 20;89(2):97-106.

21. Michael A, Jenaway A, Paykel ES, Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry. 2000 Nov 15;48(10):989-95.

22. Basar MM, Aydin G, Mert HC, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005 Sep;66(3):597-601.

23. Muller M, Grobbee DE, den T, I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005 May;90(5):2618-23.

24. Genazzani AR, Inglese S, Lombardi I, et al. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency. Aging Male. 2004 Jun;7(2):133-43.

25. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci. 1997 Jan;52(1):M1-M7.

26. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006 Oct 24;114(17):1829-37.

27. Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab. 2000 May;85(5):1834-40.

28. Sacco M, Valenti G, Corvi MP, Wu FC, Ray DW. DHEA, a selective glucocorticoid receptor antagonist: its role in immune system regulation and metabolism. J Endocrinol Invest. 2002;25(10 Suppl):81-2.

29. Roberts E. The importance of being dehydroepiandrosterone sulfate (in the blood of primates): a longer and healthier life? Biochem Pharmacol. 1999 Feb 15;57(4):329-46.

30. Williams JR. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging. Lipids. 2000 Mar;35(3):325-31.

31. Valenti G, Denti L, Maggio M, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004 May;59(5):466-72.

32. Jesse RL, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci. 1995 Dec 29;774:281-90.

33. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 1993 Dec;169(6):1536-9.

34. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003 Jul;88(7):3190-5.

35. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005 Mar;54(3):765-9.

36. Casson PR, Faquin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995 May;63(5):1027-31.

37. Sun Y, Mao M, Sun L, et al. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chin Med J (Engl). 2002 Mar;115(3):402-4.

38. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf). 2000 Nov;53(5):561-8.

39. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997 Oct;82(10):3498-505.

40. Adachi M, Takayanagi R. Role of androgens and DHEA in bone metabolism. Clin Calcium. 2006 Jan;16(1):61-6.

41. Aoki K, Nakajima A, Mukasa K, et al. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):469-72.

42. Prough RA, Lei XD, Xiao GH, et al. Regulation of cytochromes P450 by DHEA and its anticarcinogenic action. Ann NY Acad Sci. 1995 Dec 29;774:187-99.

43. Schwartz AG, Pashko LL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Suppl. 1995;22:210-7.

44. Inano H, Ishii-Ohba H, Suzuki K, et al. Chemoprevention by dietary dehydroepiandrosterone against promotion/progression phase of radiation-induced mammary tumorigenesis in rats. J Steroid Biochem Mol Biol. 1995 Jul;54(1-2):47-53.

45. Melvin WS, Boros LG, Muscarella P, et al. Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery. 1997 Apr;121(4):392-7.

46. Moore MA, Weber E, Thornton M, Bannasch P. Sex-dependent, tissue-specific opposing effects of dehydroepiandrosterone on initiation and modulation stages of liver and lung carcinogenesis induced by dihydroxy-di-n-propylnitrosamine in F344 rats. Carcinogenesis. 1988 Aug;9(8):1507-9.

47. Osawa E, Nakajima A, Yoshida S, et al. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). Life Sci. 2002 Apr 19;70(22):2623-30.

48. Yang S, Fu Z, Wang F, Cao Y, Han R. Anti-mutagenicity activity of dehydroepiandrosterone. Zhonghua Zhong Liu Za Zhi. 2002 Mar;24(2):137-40.

49. Yoshida S, Honda A, Matsuzaki Y, et al. Antiproliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids. 2003 Jan;68(1):73-83.

50. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999 Sep 30;341(14):1013-20.

51. Herbert J. Neurosteroids, brain damage, and mental illness. Exp Gerontol. 1998 Nov;33(7-8):713-27.

52. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005 Feb;62(2):154-62.

53. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994 Jun;78(6):1360-7.

54. Juhasz-Vedres G, Rozsa E, Rakos G, et al. Dehydroepiandrosterone sulfate is neuroprotective when administered either before or after injury in a focal cortical cold lesion model. Endocrinology. 2006 Feb;147(2):683-6.

55. Parsons TD, Kratz KM, Thompson E, Stanczyk FZ, Buckwalter JG. Dhea supplementation and cognition in postmenopausal women. Int J Neurosci. 2006 Feb;116(2):141-55.

56. de B, V, Vieira MC, Rocha MN, Viana GS. Cortisol and dehydroepiandosterone sulfate plasma levels and their relationship to aging, cognitive function, and dementia. Brain Cogn. 2002 Nov;50(2):316-23.

57. Magri F, Terenzi F, Ricciardi T, et al. Association between changes in adrenal secretion and cerebral morphometric correlates in normal aging and senile dementia. Dement Geriatr Cogn Disord. 2000 Mar;11(2):90-9.

58. Karishma KK, Herbert J. Dehydroepiandro-sterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci. 2002 Aug;16(3):445-53.

59. Mills SJ, Ashworth JJ, Gilliver SC, Hardman MJ, Ashcroft GS. The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors. J Invest Dermatol. 2005 Nov;125(5):1053-62.

60. Ayhan S, Markal N, Siemionow K, Araneo B, Siemionow M. Effect of subepineurial dehydroepiandrosterone treatment on healing of transected nerves repaired with the epineurial sleeve technique. Microsurgery. 2003;23(1):49-55.

61. Nordmark G, Bengtsson C, Larsson A et al. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005 Nov;38(7):531-40.

62. Steel N. Dehydro-epiandrosterone and ageing. Age Ageing. 1999 Mar;28(2):89-91.

63. Available at: Accessed April 1, 2007.

64. Available at: Accessed April 1, 2007.

65. Hougaku H, Fleg JL, Najjar SS, et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006 Feb;290(2):E234-42.

66. Alwardt CM, Yu Q, Brooks HL, et al. Comparative effects of dehydroepiandrosterone sulfate on ventricular diastolic function with young and aged female mice. Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R251-6.

67. Hutchison SJ, Browne AE, Ko E, et al. Dehydroepiandrosterone sulfate induces acute vasodilation of porcine coronary arteries in vitro and in vivo. J Cardiovasc Pharmacol. 2005 Sep;46(3):325-32.

68. Martina V, Benso A, Gigliardi VR, et al. Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clin Endocrinol (Oxf). 2006 Mar;64(3):260-4.

69. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986 Dec 11;315(24):1519-24.

70. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32.

71. Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 May;90(5):2740-6.

72. Shimizu T, Choudhry MA, Szalay L, et al. Salutary effects of androstenediol on cardiac function and splanchnic perfusion after trauma-hemorrhage. Am J Physiol Regul Integr Comp Physiol. 2004 Aug;287(2):R386-90.

73. Origlia C, Pescarmona G, Capizzi A, et al. Platelet cGMP inversely correlates with age in healthy subjects. J Endocrinol Invest. 2004 Feb;27(2):RC1-4.

74. Okamoto K. Relationship between dehydroepiandrosterone sulfate and serum lipid levels in Japanese men. J Epidemiol. 1996 Jun;6(2):63-7.

75. Shono N, Kumagai S, Higaki Y, Nishizumi M, Sasaki H. The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. J Atheroscler Thromb. 1996;3(1):45-51.

76. Cardounel A, Regelson W, Kalimi M. Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med. 1999 Nov;222(2):145-9.

77. Garcia-Estrada J, Luquin S, Fernandez AM, Garcia-Segura LM. Dehydroepiandrosterone, pregnenolone and sex steroids down-regulate reactive astroglia in the male rat brain after a penetrating brain injury. Int J Dev Neurosci. 1999 Apr;17(2):145-51.

78. Kalmijn S, Launer LJ, Stolk RP, et al. A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J Clin Endocrinol Metab. 1998 Oct;83(10):3487-92.

79. Carlson LE, Sherwin BB, Chertkow HM. Relationships between dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels and everyday memory in Alzheimer’s disease patients compared to healthy controls. Horm Behav. 1999 Jun;35(3):254-63.

80. Murialdo G, Nobili F, Rollero A, et al. Hippocampal perfusion and pituitary-adrenal axis in Alzheimer’s disease. Neuropsychobiology. 2000;42(2):51-7.

81. Li H, Klein G, Sun P, Buchan AM. Dehydroepiandrosterone (DHEA) reduces neuronal injury in a rat model of global cerebral ischemia. Brain Res. 2001 Jan 12;888(2):263-6.

82. Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor alpha and interleukin-6 [correction of interlukin-6] in astrocytes. Int J Dev Neurosci. 1999 Dec;17(8):765-75.

83. Young AH, Gallagher P, Porter RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry. 2002 Jul;159(7):1237-9.

84. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry. 2003 Feb;60(2):133-41.

85. Young AH, Gallagher P, Porter RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry. 2002 Jul;159(7):1237-9.

86. Valtysdottir ST, Wide L, Hallgren R. Mental wellbeing and quality of sexual life in women with primary Sjogren’s syndrome are related to circulating dehydroepiandrosterone sulphate. Ann Rheum Dis. 2003 Sep;62(9):875-9.

87. Jozuka H, Jozuka E, Takeuchi S, Nishikaze O. Comparison of immunological and endocrinological markers associated with major depression. J Int Med Res. 2003 Jan;31(1):36-41.

88. Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St CL. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology. 2002 Nov;27(8):907-20.

89. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry. 1999 Jun 15;45(12):1533-41.

90. Wolkowitz OM, Reus VI. Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression. World J Biol Psychiatry. 2003 Jul;4(3):98-102.

91. van BF, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl). 2003 Jan;165(2):97-110.

92. Wolkowitz OM, Reus VI, Roberts E, et al. Antidepressant and cognition-enhancing effects of DHEA in major depression. Ann NY Acad Sci. 1995 Dec 29;774:337-9.

93. Meno-Tetang GM, Blum RA, Schwartz KE, Jusko WJ. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. J Clin Pharmacol. 2001 Nov;41(11):1195-205.

94. Valenti G. Andrenopause: an imbalance between dehydroepiandrosterone (DHEA) and cortisol secretion. J Endocrinol Invest. 2002 25(10 suppl):29- 35.

95. Genazzani AD, Lanzoni C, Genazzani AR. Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging. 2007;24(3):173-85.

96. Wojtal K, Trojnar MK, Czuczwar SJ. Endogenous neuroprotective factors: neurosteroids. Pharmacol Rep. 2006 May;58(3):335-40.

97. Strous RD. Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology. Essent Psychopharmacol. 2005;6(3):141-7.

98. Ferrari E, Casarotti D, Muzzoni B, et al. Age-related changes of the adrenal secretory pattern: possible role in pathological brain aging. Brain Res Brain Res Rev. 2001 Nov;37(1-3):294-300.

99. Lai DY. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2004 May;22(1):37-55.

100. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ.Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol. 1993 Nov;31(11):857-907.

101. Metzger C, Bannasch P, Mayer D. Enhancement and phenotypic modulation of N-nitrosomorpholine-induced hepatocarcinogenesis by dehydroepiandrosterone. Cancer Lett. 1997 Dec 23;121(2):125-31.

102. Imai K, Kudo N, Koyam M, Shirahata A, Kawashim Y.Effects of dehydroepiandrosterone on oleic acid formation in the liver of rats, mice and guinea pigs. Jpn J Pharmacol. 2001 Aug;86(4):437-47.

103. Sakuma M, Yamada J, Suga T. Comparison of the inducing effect of dehydroepiandrosterone on hepatic peroxisome proliferation-associated enzymes in several rodent species. A short-term administration study. Biochem Pharmacol. 1992 Mar 17;43(6):1269-73.

104. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):87-93.

105. Morrell MJ, Flynn KL, Done S, et al. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav. 2005 May;6(3):360-5.

106. Santoro N, Torrens J, Crawford S et al. Correlates of circulating androgens in mid-life women: the study of women’s health across the nation. J Clin Endocrinol Metab. 2005 Aug;90(8):4836-45.

107. Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol. 2003 Nov;21(5):346-55.

108. Arlt W. Androgen therapy in women. Eur J Endocrinol. 2006 Jan;154(1):1-11.

109. Simile M, Pascale RM, De Miglio MR, et al. Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis. Int J Cancer. 1995 Jul 17;62(2):210-5.

110. Green JE, Shibata MA, Shibata E, et al. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001 Oct 15;61(20):7449-55.

111. Lubet RA, Gordon GB, Prough RA, et al. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res. 1998 Mar 1;58(5):921-6.

112. Perkins SN, Hursting SD, Haines DC, et al. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis. 1997 May;18(5):989-94.

113. Ciolino H, MacDonald C, Memon O, Dankwah M, Yeh GC. Dehydroepiandrosterone inhibits the expression of carcinogen-activating enzymes in vivo. Int J Cancer. 2003 Jun 20;105(3):321-5.

114. Loria RM. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids. 2002 Nov;67(12):953-66.

115. Bradlow HL, Sepkovic DW. Diet and breast cancer. Ann NY Acad Sci. 2002 Jun;963:247-67.

116. Solerte SB, Fioravanti M, Vignati G, et al. Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. J Clin Endocrinol Metab. 1999 Sep;84(9):3260-7.

117. Mei JJ, Hursting SD, Perkins SN, Phang JM. p53-independent inhibition of nitric oxide generation by cancer preventive interventions in ex vivo mouse peritoneal macrophages. Cancer Lett. 1998 Jul 17;129(2):191-7.

118. D’Ambrosio SM, Gibson-D’Ambrosio RE, Wani G, et al. Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res. 2001 Sep;21(5):3229-35.

119. Weber E, Moore MA, Bannasch P. Phenotypic modulation of hepatocarcinogenesis and reduction in N-nitrosomorpholine-induced hemangiosarcoma and adrenal lesion development in Sprague-Dawley rats by dehydroepiandrosterone. Carcinogenesis. 1988 Jul;9(7):1191-5.

120. Prough RA, Lei XD, Xiao GH, et al. Regulation of cytochromes P450 by DHEA and its anticarcinogenic action. Ann NY Acad Sci. 1995 Dec 29;774:187-99.

121. Schwartz AG and Pashko LL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Suppl. 1995;22:210-7.

122. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Cancer Epidemiol Biomarkers Prev. 1995 Oct;4(7):691-702.

123. Melvin WS, Boros LG, Muscarella P, et al. Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery. 1997 Apr;121(4):392-7.

124. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res. 1995 Sep 15;55(18):3949-53.

125. Ledochowski M, Murr C, Jager M, Fuchs D. Dehydroepiandrosterone, ageing and immune activation. Exp Gerontol. 2001 Nov;36(10):1739-47.

126. Williams JR. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging. Lipids. 2000 Mar;35(3):325-31.

127. Kavanaugh C, Green JE. The use of genetically altered mice for breast cancer prevention studies. J Nutr. 2003 Jul;133(7 Suppl):2404S-9S.

128. Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression—a single case report. Curr Med Res Opin. 2003;19(1):59-63.

129. Yang NC, Jeng KC, Ho WM, Hu ML. ATP depletion is an important factor in DHEA-induced growth inhibition and apoptosis in BV-2 cells. Life Sci. 2002 Mar 15;70(17):1979-88.

130. Schulz S, Klann RC, Schonfeld S, Nyce JW. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Res. 1992 Mar 1;52(5):1372-6.

131. Dashtaki R, Whorton AR, Murphy TM, et al. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther. 1998 May;285(2):876-83.

132. Wang TT, Hursting SD, Perkins SN, Phang JM. Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/Bax-mediated apoptotic pathway in p53-deficient mice. Cancer Lett. 1997 Jun 3;116(1):61-9.

133. Regelson W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA—the “mother steroid.” I. Immunologic action. Ann NY Acad Sci. 1994 May 31;719:553-63.

134. Perkins SN, Hursting SD, Kim K, Poetschke K, Heather L, Richie ER. Mechanisms underlying the anti-lymphoma activity of dehydroepiandrosterone: studies in murine thymocytes and murine T-cell hybridoma cells. cancer Epidem Biomark Prevent. 2002;11(10):1233s.

135. Hsu HC. Dehydroepiandrosterone (DHEA) sulfotransferase gene expression in human hepatocellular carcinoma: an age-dependent prognostic factor. Proc Am Assoc Cancer Res. 1995;36:208.

136. Osawa E, Nakajima A, Yoshida S, et al. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). Life Sci. 2002 Apr 19;70(22):2623-30.

137. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet. 1971 Aug 21;2(7721):395-8.

138. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999 Jun;80(7):930-4.

139. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):967-9.

140. Stahl F, Schnorr D, Pilz C, Dorner G. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol. 1992;99(2):68-70.

141. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001 Apr;47(1):52-8.

142. Schatzl G, Reiter WJ, Thurridl T, et al. Endocrine patterns in patients with benign and malignant prostatic diseases. Prostate. 2000 Aug 1;44(3):219-24.

143. Huot RI, Shain SA. Differential metabolism of dehydroepiandrosterone sulfate and estrogen conjugates by normal or malignant AXC/SSh rat prostate cells and effects of these steroid conjugates on cancer cell proliferation in vitro. J Steroid Biochem. 1988 Jun;29(6):617-21.

144. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever Rat. Eur Urol. 1999 May;35(5-6):464-7.

145. Ponholzer A, Plas E, Schatzl G, Jungwirth A, Madersbacher S. Association of DHEA-S and estradiol serum levels to symptoms of aging men. Aging Male. 2002 Dec;5(4):233-8.

146. Longcope C. Dehydroepiandrosterone metabolism. J Endocrinol. 1996 Sep;150 SupplS125-7.

147. Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc. 1999 Dec;31(12):1788-92.

148. Brown GA, Vukovich MD, Sharp RL, et al. Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J Appl Physiol. 1999 Dec;87(6):2274-83.

149. Brown GA, Vukovich MD, Reifenrath TA, et al. Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men. Int J Sport Nutr Exerc Metab. 2000 Sep;10(3):340-59.

150. Available at: Accessed April 1, 2007.

151. Welle S, Jozefowicz R, Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab. 1990 Nov;71(5):1259-64.

152. Nissen SL, Sharp RL. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. J Appl Physiol. 2003 Feb;94(2):651-9.

153. Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol. 2004 Dec;4(6):614-20.

154. Delbeke FT, Van EP, Van TW, Desmet N. Prohormones and sport. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):245-51.

155. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-54.

156. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):55-69.

157. Pope HG. Current state of DHEA in the marketplace. Washington, DC: Council for Responsible Nutrition; 2003.